Metin Çelik, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Metin Çelik, PhD


Metin Çelik, PhD
President, Pharmaceutical
Technologies
International (PTI)

Metin Çelik is the founder and president of Pharmaceutical Technologies International, Inc., and is also a pharmaceutical processing research professor in the Department of Industrial Engineering at Rutgers University. Prior to that, he was a faculty member at Rutgers’ College of Pharmacy. Çelik received his BSc (Hons.) degree in pharmacy from Hacettepe University-Turkey and was awarded a PhD degree in Pharmaceutical Technology from Leicester Polytechnic-UK. Çelik worked at Sandoz-Switzerland and Sandoz-Turkey before he joined Smith Kline & French Laboratories to establish the first state-of-the-art compaction simulator system in the western hemisphere. He developed the second unit at Rutgers as the first such a unit in academia in the US and established an internationally recognized research center.

Çelik has organized more than 40 national and international symposia and short courses, published more than 30 research articles and book chapters, and made more than 150 presentations at industry and academic meetings. Çelik acted a consultant to FDA and roughly 45 pharmaceutical, nutraceutical, excipient, equipment companies, and law firms worldwide. He currently serves as a member of the editorial board or a reviewer for a numerous pharmaceutical journals. He is the past chair of the American Association of Pharmaceutical Scientists (AAPS) Process Development Focus Group and the founder and the past chair of the AAPS Excipients Focus Group.

Çelik's recent areas of interests include: process analytical technology; development of pharmaceutical expert systems, excipient databases, and management tools in the area of drug delivery technologies; use of compaction simulators in the preformulation and formulation of solid dosage forms; theory and practice of pharmaceutical compaction; excipient functionality testing; and pharmaceutical processing (including milling, mixing, granulation, tableting, and coating).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here